Advancing Antimicrobial Innovation
Through Science
Natureza® Research Addresses the Urgency of Antimicrobial Resistance
THE PROBLEM:
Antimicrobial-Resistant infections are rising worldwide, yet the development pathway remains weak (WHO 2019). Developing a novel antimicrobial approach takes 10–15 years and over $1 billion, but resistance can emerge within months, discouraging innovation—only two new classes have been created in 40 years. Lab studies show resistance evolving in days (Baym et al. 2016). We urgently need antibiotics with novel targets that resist resistance. Most critical pathogens are Gram-negative ESKAPE organisms, though some Gram-positives, like vancomycin-resistant Enterococcus faecium, are also high priority. New solutions must not only kill resistant bacteria but also prevent resistance from developing.
A SOLUTION:
Extensive laboratory studies have demonstrated that Natureza’s antimicrobial active systems exhibit strong in-vitro activity against challenging and highly resistant organisms, including Candida auris and Pseudomonas aeruginosa. Building on these findings, the Company is advancing development through non-clinical laboratory validation focused on formulation performance, durability, and application-specific use cases. By targeting non-systemic surface and topical applications, this approach is designed to reduce the selective pressures that commonly drive resistance, while significantly lowering development timelines and regulatory complexity. This strategy enables faster translation of validated antimicrobial performance into real-world solutions and creates a capital-efficient pathway toward commercial and public-health impact.
ABOUT NATUREZA® RESEARCH
Natureza® Research builds on scientific and technical work initiated by its parent company, BioSafe Technologies, Inc., a Texas-based organization founded in 2000 that has supported early-stage research in antimicrobial and antiparasitic technologies. This work has focused on the identification and formulation of bioactive compounds with potential applications in microbial control and infection prevention.
Natureza® Research, Inc. holds a portfolio of U.S. and international patents and patent applications covering antimicrobial agents, formulation approaches, and related use cases. Laboratory studies conducted to date have demonstrated in-vitro activity across a range of Gram-negative and Gram-positive organisms, including pathogens identified by the World Health Organization as priority threats. These findings form the scientific foundation for Natureza’s current development efforts, which are focused on non-systemic antimicrobial applications and formulation performance rather than clinical drug development.
THE NATUREZA® TEAM
The Natureza® Research team brings together experience in infectious disease research, formulation science, and early-stage technology development. The team’s work draws on academic research, applied science, and international collaboration to evaluate antimicrobial mechanisms and translate laboratory findings into practical, non-systemic applications.
Guided by a commitment to scientific rigor and responsible development, the team’s focus is on advancing validated antimicrobial technologies through disciplined research, formulation optimization, and non-clinical evaluation, while maintaining flexibility for future development pathways.
This work is supported by issued and pending U.S. and international patents covering antimicrobial compositions, formulation methods, and related use cases.
Advancing Antimicrobial Innovation Through Science
Natureza® Research Addresses the Urgency of Antimicrobial Resistance
THE PROBLEM:
Antimicrobial-Resistant infections are rising worldwide, yet the development pathway remains weak (WHO 2019). Developing a novel antimicrobial approach takes 10–15 years and over $1 billion, but resistance can emerge within months, discouraging innovation—only two new classes have been created in 40 years. Lab studies show resistance evolving in days (Baym et al. 2016). We urgently need antibiotics with novel targets that resist resistance. Most critical pathogens are Gram-negative ESKAPE organisms, though some Gram-positives, like vancomycin-resistant Enterococcus faecium, are also high priority. New solutions must not only kill resistant bacteria but also prevent resistance from developing.
A SOLUTION:
Extensive laboratory studies have demonstrated that Natureza’s antimicrobial active systems exhibit strong in-vitro activity against challenging and highly resistant organisms, including Candida auris and Pseudomonas aeruginosa. Building on these findings, the Company is advancing development through non-clinical laboratory validation focused on formulation performance, durability, and application-specific use cases. By targeting non-systemic surface and topical applications, this approach is designed to reduce the selective pressures that commonly drive resistance, while significantly lowering development timelines and regulatory complexity. This strategy enables faster translation of validated antimicrobial performance into real-world solutions and creates a capital-efficient pathway toward commercial and public-health impact.
ABOUT NATUREZA® RESEARCH
Natureza® Research builds on scientific and technical work initiated by its parent company, BioSafe Technologies, Inc., a Texas-based organization founded in 2000 that has supported early-stage research in antimicrobial and antiparasitic technologies. This work has focused on the identification and formulation of bioactive compounds with potential applications in microbial control and infection prevention.
Natureza® Research, Inc. holds a portfolio of U.S. and international patents and patent applications covering antimicrobial agents, formulation approaches, and related use cases. Laboratory studies conducted to date have demonstrated in-vitro activity across a range of Gram-negative and Gram-positive organisms, including pathogens identified by the World Health Organization as priority threats. These findings form the scientific foundation for Natureza’s current development efforts, which are focused on non-systemic antimicrobial applications and formulation performance rather than clinical drug development.
THE NATUREZA® TEAM
The Natureza® Research team brings together experience in infectious disease research, formulation science, and early-stage technology development. The team’s work draws on academic research, applied science, and international collaboration to evaluate antimicrobial mechanisms and translate laboratory findings into practical, non-systemic applications.
Guided by a commitment to scientific rigor and responsible development, the team’s focus is on advancing validated antimicrobial technologies through disciplined research, formulation optimization, and non-clinical evaluation, while maintaining flexibility for future development pathways.
This work is supported by issued and pending U.S. and international patents covering antimicrobial compositions, formulation methods, and related use cases.
